We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Gymnema Sylvestre vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 5.5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Gymnema Sylvestre and Tirzepatide have evidence — compare verdict strength side-by-side.
200-400mg standardized extract (≥25% gymnemic acids) 1-2x daily, or 2-4g dried leaf
with-meals
Standardized extract (≥25% gymnemic acids)
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
any
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
8-12 weeks
Immediate-2 weeks
8-12 weeks
Days
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis.
Phytotherapy research : PTR (2021) · Meta analysis
Significant reductions in fasting blood glucose and HbA1c versus control
The effects of Gymnema Sylvestre supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults: A systematic review and meta-analysis.
Phytotherapy research : PTR (2023) · Meta analysis
Reductions in fasting glucose and improvements in lipid profile
A systematic review of Gymnema sylvestre in obesity and diabetes management.
Journal of the science of food and agriculture (2014) · Systematic review
Possible benefits for glycemic control and body weight
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Tirzepatide has a higher evidence score (7.8/10 vs 5.5/10) and wins in 2 of 3 categories.
For manage weight, Tirzepatide has a higher relevance score (90 vs 60).
No known interactions between Gymnema Sylvestre and Tirzepatide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.